

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Weaver, Donald F. et al.

Serial No.: 09/932676

Filed: August 16, 2001

For: ANTI-EPILEPTOGENIC AGENTS

Attorney Docket No.: NCI-006DV2

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Group Art Unit: 1624

Examiner: Rao, Deepak R.

RECEIVED

TECH CENTER 1600/2900

"Express Mail" mailing label number EV 355388883 US
1 -14
Date of Deposit
•
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents,
, and the second se
P.O. Box 1450, Alexandria, Virginia 22313-1450.
Mark
Signature
Elizabeth A. Hanley, Esq.
Please Print Name of Person Signing

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed October 7, 2003 during the prosecution of PCT/CA02/00363 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form SB/08, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be

Serial Number: 09/932676 Page -2- Group Art Unit: 1624

construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(d), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was received by the undersigned on October 15, 2003 (not more than three months prior to the filing of this statement) from the Canadian associate that received the references in a communication from a foreign patent office in a counterpart foreign application on October 7, 2003.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted, LAHIVE & COCKFIELD, LLP

Elizabeth A. Hankey, Esq Registration No. 33,505 Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: 1/15/04

GAD/EAH/JGW/krj

Enclosures

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

NCI-006DV2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/B/PTO 09/932676 Application Number INFORMATION DISCLOSURE August 16, 2001 Filing Date STATEMENT BY APPLICANT Weaver, Donald F. First Named Inventor Art Unit 1624 (Use as many sheets as necessary) Rao, Deepak R. Examiner Name

Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

Sheet

1

of

1

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	D1	WO 98/40055 A2, A3	09-17-1998	QUEEN'S UNIVERSITY AT KINGSTON [CA/CA]			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
D2	Bigge, C.F. et al. "Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and <i>N</i> -methyl-D-aspartate) receptor and anticonvulsant activity." <i>J. Med. Chem.</i> 38:3720-3740 (1995).	
D3	Ho, B. et al. "Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores." Eur. J. Med. Chem. 36:265-286 (2001)	
D4	Ling, R. et al. "Synthesis of 4-alkyl-pyrrolidine-3-carboxylic acid stereoisomers." Tetrahedron 57:6579-6588 (2001)	
	No.1 D2 D3	 No.¹ magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. D2 Bigge, C.F. et al. "Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity." J. Med. Chem. 38:3720-3740 (1995). D3 Ho, B. et al. "Synthesis and structure-activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores." Eur. J. Med. Chem. 36:265-286 (2001) D4 Ling, R. et al. "Synthesis of 4-alkyl-pyrrolidine-3-carboxylic acid stereoisomers." Tetrahedron

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.